162 related articles for article (PubMed ID: 16198632)
1. Pharmacological management of pancreatitis.
Hoogerwerf WA
Curr Opin Pharmacol; 2005 Dec; 5(6):578-82. PubMed ID: 16198632
[TBL] [Abstract][Full Text] [Related]
2. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
4. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
5. Antiproteases in preventing post-ERCP acute pancreatitis.
Tsujino T; Kawabe T; Omata M
JOP; 2007 Jul; 8(4 Suppl):509-17. PubMed ID: 17625308
[TBL] [Abstract][Full Text] [Related]
6. Prevention of post-ERCP pancreatitis.
Haber GB
Gastrointest Endosc; 2000 Jan; 51(1):100-3. PubMed ID: 10625814
[No Abstract] [Full Text] [Related]
7. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.
Zhang ZF; Yang N; Zhao G; Zhu L; Zhu Y; Wang LX
Chin Med J (Engl); 2010 Sep; 123(18):2600-6. PubMed ID: 21034635
[TBL] [Abstract][Full Text] [Related]
8. [Can post-ERCP acute pancreatitis be predicted and prevented?].
Heyries L
Gastroenterol Clin Biol; 2001 Jan; 25(1 Suppl):1S241-6. PubMed ID: 11223596
[No Abstract] [Full Text] [Related]
9. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study.
Rudin D
Gastrointest Endosc; 2008 Jan; 67(1):190; author reply 190-1. PubMed ID: 18155442
[No Abstract] [Full Text] [Related]
14. Predicting and preventing post-ERCP pancreatitis.
Baillie J
Curr Gastroenterol Rep; 2002 Apr; 4(2):112-9. PubMed ID: 11900675
[TBL] [Abstract][Full Text] [Related]
15. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
Poon RT; Fan ST
JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
[TBL] [Abstract][Full Text] [Related]
16. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
17. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
18. Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis.
Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
Am J Med Sci; 2016 May; 351(5):506-12. PubMed ID: 27140710
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Pande H; Thuluvath P
Drugs; 2003; 63(17):1799-812. PubMed ID: 12921486
[TBL] [Abstract][Full Text] [Related]
20. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp?
Chen S; Shi H; Zou X; Luo H
Pancreas; 2010 Nov; 39(8):1231-7. PubMed ID: 20531245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
